Literature DB >> 28831695

Evaluation of pharmacokinetic model designs for subcutaneous infusion of insulin aspart.

Erin J Mansell1, Signe Schmidt2,3, Paul D Docherty4, Kirsten Nørgaard2, John B Jørgensen5, Henrik Madsen5.   

Abstract

Effective mathematical modelling of continuous subcutaneous infusion pharmacokinetics should aid understanding and control in insulin therapy. Thorough analysis of candidate model performance is important for selecting the appropriate models. Eight candidate models for insulin pharmacokinetics included a range of modelled behaviours, parameters and complexity. The models were compared using clinical data from subjects with type 1 diabetes with continuous subcutaneous insulin infusion. Performance of the models was compared through several analyses: R2 for goodness of fit; the Akaike Information Criterion; a bootstrap analysis for practical identifiability; a simulation exercise for predictability. The simplest model fit poorly to the data (R2 = 0.53), had the highest Akaike score, and worst prediction. Goodness of fit improved with increasing model complexity (R2 = 0.85-0.92) but Akaike scores were similar for these models. Complexity increased practical non-identifiability, where small changes in the dataset caused large variation (CV > 10%) in identified parameters in the most complex models. Best prediction was achieved in a relatively simple model. Some model complexity was necessary to achieve good data fit but further complexity introduced practical non-identifiability and worsened prediction capability. The best model used two linear subcutaneous compartments, an interstitial and plasma compartment, and two identified variables for interstitial clearance and subcutaneous transfer rate. This model had optimal performance trade-off with reasonable fit (R2 = 0.85) and parameterisation, and best prediction and practical identifiability (CV < 2%).

Entities:  

Keywords:  Continuous subcutaneous insulin infusion; Goodness of fit; Parameter identification; Pharmacokinetic modelling; Practical identifiability; Type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28831695     DOI: 10.1007/s10928-017-9535-z

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  35 in total

1.  A physiological Intensive Control Insulin-Nutrition-Glucose (ICING) model validated in critically ill patients.

Authors:  Jessica Lin; Normy N Razak; Christopher G Pretty; Aaron Le Compte; Paul Docherty; Jacquelyn D Parente; Geoffrey M Shaw; Christopher E Hann; J Geoffrey Chase
Journal:  Comput Methods Programs Biomed       Date:  2011-02-01       Impact factor: 5.428

2.  Structural and practical identifiability analysis of partially observed dynamical models by exploiting the profile likelihood.

Authors:  A Raue; C Kreutz; T Maiwald; J Bachmann; M Schilling; U Klingmüller; J Timmer
Journal:  Bioinformatics       Date:  2009-06-08       Impact factor: 6.937

3.  Estimation of secondary effect parameters in glycaemic dynamics using accumulating data from a virtual type 1 diabetic patient.

Authors:  Erin J Mansell; Paul D Docherty; Liam M Fisk; J Geoffrey Chase
Journal:  Math Biosci       Date:  2015-06-17       Impact factor: 2.144

4.  Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.

Authors:  P D Home; L Barriocanal; A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1999-05       Impact factor: 2.953

5.  Population pharmacokinetic model of human insulin following different routes of administration.

Authors:  Elizabeth Potocka; Robert A Baughman; Hartmut Derendorf
Journal:  J Clin Pharmacol       Date:  2010-10-12       Impact factor: 3.126

Review 6.  Clinical pharmacokinetics and pharmacodynamics of insulin aspart.

Authors:  A Lindholm; L V Jacobsen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

7.  Comparison of a luminescent oxygen channeling immunoassay and an ELISA for detecting insulin aspart in human serum.

Authors:  Signe Beck Petersen; Julie Mangor Lovmand; Lone Honoré; Claus Bekker Jeppesen; Lone Pridal; Ole Skyggebjerg
Journal:  J Pharm Biomed Anal       Date:  2009-08-14       Impact factor: 3.935

8.  Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects.

Authors:  S Kang; F M Creagh; J R Peters; J Brange; A Vølund; D R Owens
Journal:  Diabetes Care       Date:  1991-07       Impact factor: 19.112

9.  Incorporating a generic model of subcutaneous insulin absorption into the AIDA v4 diabetes simulator. 3. Early plasma insulin determinations.

Authors:  Eldon D Lehmann; Cristina Tarín; Jorge Bondia; Edgar Teufel; Tibor Deutsch
Journal:  J Diabetes Sci Technol       Date:  2009-01

10.  Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior.

Authors:  R P Eaton; R C Allen; D S Schade; K M Erickson; J Standefer
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

View more
  1 in total

1.  The Effects of Additional Local-Mixing Compartments in the DISST Model-Based Assessment of Insulin Sensitivity.

Authors:  Nicholas Lam; Rua Murray; Paul D Docherty; Lisa Te Morenga; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2021-06-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.